objectives. This investigation sought to determine whether endothelium-derived nitric oxide contributes to hypoxia-induced systemic vasodilation and pulmonay vasoconstriction in humans.
who inspired a mixture of nitrogen and oxygen through a gas blender adjusted to reduce the partial pressure of oxygen fkom (mean 5~ SE) 98 -+ 4 to 48 5~ 1 mm Hg.
Resuk During normoxia, L-NMMA increased systemic vascular resistance from P,PDtl -C 74 to 1,705 +-87 dynesscm-' and increased pulmonary vascular resisfance from 60 +-5 to 1.15 -c 9 dynes-scmq5 (p C 0.01 for each). Peak effects occurred within 10 min of L-NMMA administralion. Acute hypoxia alone decreased systemic vascular resistance from 1,209 2 78 to 992 a 58 dynesscmW5 (p % 0.05) and increased pulmonary vascular resistance fmm 92 9~ 11 to 136 * 4 dynessTm+ (p 5 0.01). Wile bypoxic conditions were maintained, infusion of L-IWM. 4 increased systemic vascular resistance (to 1,496 k 97 dynes-s%m-', p 5 0.01.) and increased pulmonary vascular resistance further (to 217 k 25 dllnkes-Vcm-s, p 5 0.01).
Cunclusions Endothelium-derived nitric oxide contributes to systemic vasodilation and serves as a counterregulatory mecbanism to attenuate pulmonary vasoconslriction during acute hypoxia in healthy human subjects, (J Am COM Canliol I996;zs:s91*~ 6) Endotheiium-de.rived nitric oxide is constitutively released by the endothelium and plays a critical role in regulating basal tone in both the systemic and pulmonary vascular beds (l-4). When studied under normoxic conditions, nitric oxide synthase antagonists, such as fl-monomethyLt-aginine CL-NhrlMA), increase systemic and pulmonary vascular resistance in experimentai animals and healthy h~rtrnlm subjects (3?4). Although there arc some data indicating that endotheiium-derived nitric oxide mediates changes in vascular resistance during hypoxia, much of it is contradictory, and none have been derived from normal humans (5-19j . Accordingly, we conducted an experiment in normal human volunteers to determine the c#ects of acute hypoxia on ihc systemic and pulmonary vasculature and, specifically, to assess the role of endothciium-derived nitric oxide as a mediator of these vasomotor responses.
Subjects. The study included 12 normal volunteers f-C men, 7 women; mean [ Wemorlynamic measurements. Each subject was studied in a 23" temperature-controlled room in the postabsorptive state. Caffeine, aspirin and nonsteroidal inflammatory agents were all prohibited within 12 h of the study. Under local anestb, a and sterile conditions, a 20"gauge polyethylene catheter was inserted into the right radial artery of each subject for systemic blood pressure (BP) monitoring and arterial blood gas determinations. An 8SF Cordis sheath was placed percutaneously into the right internal jugular vein. An 8F five-lumen thermodilution catheter (Abbott Critical Care Systems) was then advanced undei continuous pressure monitoring into the pulmonary arteq to measure pulmonary capillary wedge pressure, pulmonary artery pressure (PAP) and right atria1 pressure (RAP). The catheters were attached to Gourd P23 transducers. The phlebostatic axis was estimated to be 5 cm vertically beneath the sternal angle of Lewis. All hemodynamic measurements were recorded on a Gould 4600 Physiologic Recorder. Heart rate was calculated from the mean of 10 consecutive RR intervals from an electrocardiographic signal. Cardiac output (CO) was measured by thermodilution using lo-ml boluses of room temperature normal saline as the injectate. A minimum of three cardiac output measurements were made at each point and the results averaged. Systemic vascular resistance was calculated as [(Mean BP -RAP)/CQ] X 80 and pulmonary vascular resistance as [(Mean PAP -PCWP)/CO] X 80. Both were expressed as dynesscm-", Induction of hypoxia. Study participants breathed a nitrogen-oxygen mixture through an air-oxygen blender (Puritan Bennett Corp.), with nitrogen connected to the air inlet of the blender and ~~~11 source oxygen to the oxygen inlet. By changing the proportion of the two gases through the blender unit, the fraction of inspired oxygen (Fro,) ddivered to the study subject could be precisely regulated. The blender was connected to a gas-powered demand valve in series with a non-rebreathing valve (Life Support Products, Inc.). The subject breathed through a sealed mouthpiece (Puritan Bcnnett Corp.). A nose clip was placed to ensure that no air was entrained through the nose.
Real-time measurements of the inspired oxygen content was accomplished using a digital oxygen monitor (Catalyst Research) attached to the inlet of the non-rebreathing valve. Blood oxygen saturation was approximated by finger probe oximetry (Ghmeda) and confirmed by arterial blood gas analysis of the partial pressure of oxygen (PO& Basal oxygen delivery was 21% oxygen An Fro, of between 12.8% and 34.5% was required to create hypoxic conditions, approximating a PO, of 50 mm Hg and corresponding to an oxygen saturation of 84%.
Experimental protocols. All subjects rested at least 20 min after placement of the catheters, mouthpiece and nose clip before data collection. The vascular research laboratory was kept quiet, and the lights were dimmed. Two separate experimental protocols were conducted. Protocol 1. The pharmacokinetics of the nitric oxide synthase antagonist L-NMM4 was investigated under normoxic conditions in six subjects to determine the timing of its maximal efTect and the duration of action. Normoxic conditions were maintained the entire time; nonetheless, the face mask apparatus was still used to match the conditions of the hypoxia experiment (described later). Baseline hemodynamic measurements were repeated over a 30-min period, and stability was ensured. Thereafter, L-NMMA (Ctinolfa, Switzerland) 300 mg (-4 mg/kg body weight) was infused through the side port of the Cordis sheath over 4 min. Hemodynamic measurements were taken every 10 min for the next 1 h. The dose of L-NMMA was comparable to that used safely in a previous study (4) .
Protocol 2. The role of endothelium-derived nitric oxide in regulating systemic and pulmonary vascular resistance under hypoxic conditions w-as investigated. In eight subjects, including two from the first protocol, baseline hemodynamic measurements were initially taken under normoxic conditions for -30 min. Thereafter, hypoxia was induced as previously described to reduce the PO, to ,-50 mm Hg. Hemodynamic measurements and blood gas analyses were repeated. Then, while maintaining hypoxia, L-NMMA (300 mg) was infused through the sheath. Hemodynamic measurements were obmined immediately after the completion of the L-NMMA infusion because the pharmacokinetics studies previously described found that the peak effect of L-NMMA on systemic and pulmonary vascular resistance occurred promptly and gradually dissipated after 10 min (see Results). lSLood gas analysis was performed to ensure that hypo.xic conditions had reasined stable.
Statistical analysis. All results are presented as mean value 2 SE. The effect of L-NMMA on the hemodynamic variables in Protocol 1 was analyzed by one-way analysis of variance with repeated naeasures. Post hoc comparisons between baseline and the peak hemodynamic effect of L-NMMA were made using paired two-tailed r tests. For Protocol 2, the comparisons between normoxia and hypoxia. and those between hypoxia alone and hypoxia after L-NMMA admlnistration, were made using paired two-tailed t tests. Statistical significance was accepted at the 95% confidence level (p < 0.05).
Iteesults
Pharnucokinetics of L~NMMA. In the normoxic control experiments, the peak effect of L-NMMA on blood pressure and systemic vascular resistance occurred within 1 min of completion of the L-NMMA infusion (Fig. 1) IIK (beatsimin) gj 2 5 52 r JJ I -*p 5 0.01 and ip < 0.05, baseline conditions wcus peak hemodynamic effect for each mcasurcmcnt after completion of '~~-fltonomethyl-rrarginine (L-NMMA) infusion. BP = blood prcssurc; CD = cardiac output: HR = heart rate; PAP = pulmonary artery pressure; PCW = pulmonary capillary wed& pressurtr; PVR = pulmonary vascular rcsistancc; RAP = right atrial pressure; SVK -systemic vascular rcsistancc.
-. normoxia), reflecting a 27% increase in cardiac output (p 5 0.05) a small but statistically insignificant decrease in mean blood pressure and a significant decrease in right atria1 pressure (p C= tki5) (Fig. 2) . In contrast, pulmonary vascular resistance increased 46% (p < 0.01) reflecting the increase in pulmonary artery pressure (p 5 0.05:) and decrease in pulmonary capillary wedge pressure (p CC 0.05) (i.e., the increased transpulmonary pressure gradient) (Fig. 3) .
Effect of I,-NMMA on hypoxic responses. While maintaining stable hypoxk conditions (Paz from 4X 2 1 to 47 5 I mm Hg, p = NS), intravenous infusion of L-NM&I increased mean b+jod pressure 16% (p < 0.01 vs. baseline hypoxia) and deceased cardiac output 24% (p 5 0.01) (Fig. 2,  Table 2 ). This rc~ulted in a 51% increase in systemic vascular resistance (p < O.O!), reversing the initial hypoxic-induced vasodilation. Relevant to the pulmonary circulation. L-NMMA admin&ation ~rir: hypoxra increased puln:orurq~ artery pressure 27% (p I"r U.tIj)* causing 3 furiher 60% inizase in pulnronary vascuiar resistance (p ': f).Oi) (Fig. 3 . Table 2 ).
The salient findings resulting from the present skrdy are that I) acute hypoxia causes systemic vasodihnion and puimonarv vasoconstriction in healthy human subjects; 2) endothelium-derived nitric oxide is responsible, at least in part, for the systemic vasodilation that occurs during hypoxia; and 3) endothelium-derived nitric oxide is an important counterreguiatory mechanism to attenuate hypoxia-induced pulmonary vasoconstriction, Hypoxia-mediated vascular responses. The observation that hypoxia causes peripheral vasodilation is not new and has been reported by others in experimental models as well as in humans. In a series of studies, Guyton and colleagues (20) (21) (22) (23) found that direct infusion of hypoxic blood into canine limbs or isolated arterial segments caused vasodiiation. Forearm vasodilation has been observed in humans subjected to hypoxic conditions comparable to those described in the present experiment (24) (25) (26) . Hypoxia-induced changes in systemic vascular resistance also include a vasoconstrictive component, mediated by chemoreceptor activation of the sympathetic nervous system, as well as a vasodilator component, presumably caused by local release of vasoactive substances (27) (28) (29) (30) (31) . Hypoxia causes systemic vasodilation in chemoreceptordenervaeed dogs and reduces blood pressure in humans who have undergone resection of the carotid bodies (27, 23 In our study, hypoxia decr$:ased systemic vascu!ar resistance and increased pulmonary vascular resistance. Cardiac output increased, presumably as a conseT-ence of reduced afterload, as well as from the positive inotropic and chronotropic effects of chemoreceptor-mediated zctivation of sympathetic efferents. These findings are co!,sistent with observations made previously by others, a: cited previously, and establish a framework on which we examined the contribution of endothelium-derived nitric oxide. . systemic vascular resistance. L-NMMA also increased blcod pressure and decreased cardiac output. These observations are similar to those from our previous study in which we administered L-NMMA, through a dose-titration schedule, to normal volunteers (4) . In that study, $asma nitric oxide levels were measured and decreased by 65% after L-NMMA administration. On the basis of each of these studies, we can conclude that endothelium-derived nitric oxide contributes to basal systemic vascular tone. The decline in cardiac output most likely results from increased afterload as well as from baroreflex-mediated withdrawal of sympathetic efferent activity. It is unlikely that L-NMMA has a direct negative inotropic effect because nitric oxide synthase antagonists increase contractility in isolated myocytes in vitro and autonomically denervated dogs in vivo (3.536). I,-NMMA also increased pulmonary vascular resistance, an effect that peaked 10 min after drug administration. Pulmonary vasoconstriction had also occurred in our previous study, indicating that endotheliumderived nitric oxide contributes to pulmonary vascular tone under normoxic conditions (4). In the current study, we assessed the time course of the hemodynamic effects of L-NMMA to plan the hypoxia experiments. We determined that measurements after L-NMMA administration had to be made promptly because of its short half-life, while patients remained hypoxic.
Contribution sf endobheiium-derived tiiric oxide to systemic vasudilation during hypoxia. Evidence derived from experimental models implicates the endothelium as a critical source of a vasodilator ,ubstance during hypoxia (X2,13,37-40). Hypoxia-induced relaxation of rabbit aortic and femoral artery segments is attenuated by endothelial denudation or when hemoglobin is present to quench nitric: oxide (12, 37) . These findings are consistent with bioassay experiments, in which perfusate from hypoxic cultured bovine endothelial cells or from endothelium-intact rabbit aortic segments dilate den&d arterial segments (37) . Dilation of the denuded segments is blocked by pretreatment with hemoglobin. Also, hypoxia causes coronary vasodilation and increases the cyclic guanosine monophosphate content in guine$ pig hearts ex$vd ,' (13) . These effects are inhibit& in part, 'by the nitric oxide ;
.; ' ; : ; ,,,_:; NITRIC OXIDE AND VASCULAR TONE DURING HYPOXIA synthase antagonist N"-methyl--arginine, further underscoring the contribution of nitric o&de as a mediator of hypoxiainduced vasodilation. Furthermore, when studied in rats in vivo, @-nitro-L-arginine substantially attenuates the hypotensive response to hypoxia (39) . Other endotheiium-derived vasodiiators, such as prostacyclin, may contribute also to hypoxia-induced vasodiiatfon (13, 37, 38) . The data fro:0 our study indicate that endothelium-derived nitric oxide is present and contributes to systemic vasodilation during acute hypoxia in humans, as evidenced by the increase in systemic vascular resistance that occurs when L-NMMA is administered to healthy subjects under hypoxic conditions. From these experiments, it is not possible to determine whether hypoxia actually increases the amount of nitric oxide in the systemic circulation because the degree of systemic vasoconstriction was similar when L-NMMA was administered under normoxic (Protocol 1) or hypoxic (Protocol 2) conditions. The short duration of action of L-NMMA after bolus administration precluded a direct comparison be!ween normoxia and hypoxia in the same .&jects. However, we recently completed a study that addressed this possibility. L-NMMA was infused continuously into the brachial artery of normal volunteers. The forearm vasoconstrictive response to L-NMMA was significantly greater under hypoxic than normoxic conditions, indicating that increased availability of nitric oxide accounts for a significant component of hypoxia-induced forearm vasodilation (40) .
Endothelium-derived nitric oxide counterregulates hypxic pdmonary vasoconstriction. Published reports dispute whether hypoxia results in increased (14) (15) (16) (17) (18) (19) 41, 42) or decreased (10, 11, (43) (44) (45) (46) release of nitric oxide from the pulmonary endothelium. Distinctions become apparent when one considers the experimental preparation and the severity and chronic@ of hypoxia. Endotheiium-dependent relaxation is impaired in the rings of rat (ll), rabbit (46) and porcine (10) pulmonary arteries exposed to severe hypoxia in vitro. The expression of nitric oxide synthase may be reduced with severe hypoxia, thereby limiting synthesis of nitric oxide (47) . Indeed, in other experimental models of acute and less severe hypoxia, including exvivo rat lung preparations (14) (15) (16) 42) , and in viva experiments using newborn iambs (43) , rabbits (17,B) and dogs (19), endothelium-derived nitric oxide is present and attenuates hypoxic pulmonary vasoconstriction. Another important difference between in vitro experiments and ex vivo and in vivo preparations is the size of the vessels being studied. The latter two assess the pulmonary microcirculation and as such may be more relevant to hypoxia-induced pulmonary vasoconstriction. Several studies indicate that there is decreased availability of nitric oxide during chronic states of hypoxia, For example, chronic hypoxia causes progressive loss of endothelium-dependent relaxation in the isolated rat lung prep arat& (43) . Endothelium-dependent relaxation is also less in pulmbnary artery rings excised during transplantation from patiei& $Gth chroni? 'hypox$i se&mc@ry to obstructive'ludg disease than jin , rip@ from: n+@ic st@jC&s whost: lungs bad been re%d b@u$ '"fi ~r$o' i44,. Chronic&y of &qxia might ! ' ,, influence vascular reactivity, particularly if morphologic changes in the endotheiium have occurred (4). In our study, L-NMMA increased pulmonary vascular resistance during hypoxia. This finding indicates that endotheliumderived nitric oxide is present in the pulmonary circulation of healthy humans to counterregulate acute hypoxia-induced pulmonaryvasoconstriction. These findings do not enable us to determine whether the bioavaiiabiiity of nitric oxide is affected by increased synthesis or decreased degradation. Because expression of eonstitutive nitric oxide synthase is inhibited with severe hypoxia, it is not likely that nitric oxide synthase was increased, even under less hypoxic in vivo conditions (47) . It is not known whether the level of hypoxia achieved in vivo reduces the concentration of superoxide radicals and thereby decreases inactivation of nitric oxide (48) (49) (50) .
Potential mechanisms of pulmonary vasocanstriction. We can discount reduced endothelium-derived nitric oxide as the cause of pulmonary vasoconstriction during acute hypoxia. Prostacyciin, like nitric oxide, may attenuate hypoxia-induced pulmonary vasoconstriction (18) . Other candidate mechanisms include increased endothelin and histamine levels, increased alpha-adrenergic activity and inhibition of adenosine triphosphate-sensitive potassium (KATP) channels. Endotherm release increases during hypoxia (3); yet, exogenously infused endothelin causes minimal change or even vasodilation in the pulmonary circulation (51, 52) . In animal models, histamine receptor antagonists inhibit hypoxia-induced pulmonary vasoconstriction (53) . Observations that hypoxia-induced puhnonary vasoconstriction can occur in ex vivo lung preparations and in transplanted lungs in vivo (14, 15, 43, 54) argue against a role for sympathetic activation. The findings that hypoxia causes depolarization of pulmonary artery smooth muscle cells and that KATP inhibition constricts the pulmonary circulation in fetal iambs are potentially exciting, albeit still circumstantial, evidence of a important role for this channel in mediating hypoxic vasomotor tone (55,56).
Conclusions. Acute hypoxia causes systemic vasodiiation and pulmonary vasoconstriction in healthy human subjects. We found that endothelium-derived nitric oxide modulated both of these processes, extending observations made in expcrimentai animal models. In the pulmonary circulation, endotheiiumderived nitric oxide serves as a counterregulatory mechanism to attenuate pulmonary vasoconstriction, whereas in the systemic circulation, it is present during acute hypoxia and codtributes to the resulting systemic vasodiiation.
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